- Details
- Alicia Morgans and Guru Sonpavde discuss the results of Cohort K of the EV-103 trial presented at the 2022 European Society for Medical Oncology (ESMO) Annual Congress. There remains a critical need for effective and tolerable first-line treatment options in locally advanced or metastatic urothelial cancer. In second and later-line settings, both EV and pembrolizumab have independently shown an ov...
|
- Details
- Jonathan Rosenberg joins Alicia Morgans to discuss long-term outcomes of enfortumab vedotin (EV) in patients with previously treated advanced urothelial carcinoma (UC) in the EV-301 trial. The EV-301 trial demonstrated improvements in progression-free and overall survival for patients with previously treated advanced UC who received EV compared to chemotherapy. In discussing how this updated analy...
|
- Details
- Christopher Wallis and Zach Klaassen delve into the EV-201 study. This phase 2 trial investigates the efficacy of enfortumab vedotin in treating cisplatin-ineligible patients with advanced urothelial carcinoma who have previously received PD-1 or PD-L1 inhibitors. The study, conducted across 59 sites in North America, Europe, and Asia, shows a promising objective response rate of 52%, with 20% of...
|
- Details
- Jonathan Rosenberg discusses the promising results from Cohort K, a part of a multi-cohort phase 1B/2 study examining enfortumab in combination with other agents, notably pembrolizumab. The primary endpoint, objective response rate, indicates a 64.5% response with the combination treatment. This rate is significant compared to a 45% response observed with enfortumab monotherapy. Dr. Rosenberg also...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss a publication entitled, “Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes.” This study is investigating how molecular subtypes impact pathological response and survival in patients receiving preoperative cisplatin-based chemotherapy. This study shows that tumor classification by gene expression profiling and...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss a Lancet Oncology publication on the KEYNOTE-361 trial, pembrolizumab alone, or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma: A randomized open-label phase three trial. The authors of this trial assessed outcomes with first-line pembrolizumab alone or combined with chemotherapy versus chemothe...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss the CheckMate 274 publication, “Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.” The role of adjuvant treatment in high-risk muscle-invasive urothelial carcinoma after radical surgery is not clear. The authors of this publication assigned patients with muscle-invasive urothelial carcinoma who had undergone radical surgery t...
|
- Details
- In this conversation, Arlene Siefker-Radtke and Shilpa Gupta join Patrick Hensley to discuss the role of risk-stratified neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer who are undergoing radical cystectomy. Drs. Siefker-Radtke and Gupta explain how systemic chemotherapy can be very challenging for bladder cancer patients due to the long-term side effects it can cause, alo...
|
- Details
- Alicia Morgans speaks with Robert Jones about the ATLANTIS Trial, focusing on an embedded randomization that studied the efficacy of Cabozantinib in urothelial carcinoma patients post-chemotherapy. Dr. Jones explains that the ATLANTIS platform aims to explore precision medicine in urothelial cancer and includes an "all-comers" arm to ensure broader patient participation. Unfortunately, the study f...
|
- Details
- Petros Grivas is joined by Dimitrios Makrakis to discuss his multi-institutional retrospective cohort study of patients with advanced urothelial carcinoma (UC) who received platinum-based chemotherapy in the first line, followed by second-line immune checkpoint inhibitor (ICI). In this study, the timely question of how the duration of response to immune checkpoint inhibitor may be interpreted as p...
|
